Genprex (GNPX) Competitors $0.23 -0.01 (-4.70%) As of 11:31 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GNPX vs. BCAB, EGRX, ATHE, LVTX, XLO, GBIO, PYRGF, JSPR, PLUR, and DYAIShould you be buying Genprex stock or one of its competitors? The main competitors of Genprex include BioAtla (BCAB), Eagle Pharmaceuticals (EGRX), Alterity Therapeutics (ATHE), LAVA Therapeutics (LVTX), Xilio Therapeutics (XLO), Generation Bio (GBIO), PyroGenesis Canada (PYRGF), Jasper Therapeutics (JSPR), Pluri (PLUR), and Dyadic International (DYAI). These companies are all part of the "pharmaceutical products" industry. Genprex vs. Its Competitors BioAtla Eagle Pharmaceuticals Alterity Therapeutics LAVA Therapeutics Xilio Therapeutics Generation Bio PyroGenesis Canada Jasper Therapeutics Pluri Dyadic International BioAtla (NASDAQ:BCAB) and Genprex (NASDAQ:GNPX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation. Do institutionals & insiders have more ownership in BCAB or GNPX? 77.2% of BioAtla shares are owned by institutional investors. Comparatively, 14.1% of Genprex shares are owned by institutional investors. 11.2% of BioAtla shares are owned by insiders. Comparatively, 0.4% of Genprex shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media favor BCAB or GNPX? In the previous week, Genprex had 2 more articles in the media than BioAtla. MarketBeat recorded 2 mentions for Genprex and 0 mentions for BioAtla. Genprex's average media sentiment score of 0.30 beat BioAtla's score of 0.00 indicating that Genprex is being referred to more favorably in the news media. Company Overall Sentiment BioAtla Neutral Genprex Neutral Do analysts prefer BCAB or GNPX? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioAtla 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Genprex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has preferable earnings & valuation, BCAB or GNPX? Genprex has lower revenue, but higher earnings than BioAtla. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioAtla$11M3.52-$69.78M-$1.10-0.60GenprexN/AN/A-$21.11MN/AN/A Which has more risk & volatility, BCAB or GNPX? BioAtla has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500. Comparatively, Genprex has a beta of -0.65, meaning that its share price is 165% less volatile than the S&P 500. Is BCAB or GNPX more profitable? Genprex's return on equity of -809.27% beat BioAtla's return on equity.Company Net Margins Return on Equity Return on Assets BioAtlaN/A -1,177.18% -137.51% Genprex N/A -809.27%-386.95% SummaryBioAtla beats Genprex on 6 of the 10 factors compared between the two stocks. Get Genprex News Delivered to You Automatically Sign up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNPX vs. The Competition Export to ExcelMetricGenprexMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.21M$3.14B$5.78B$10.38BDividend YieldN/A2.37%5.74%4.64%P/E RatioN/A20.9177.0826.78Price / SalesN/A431.61507.10167.11Price / CashN/A45.3237.1760.63Price / Book1.599.7413.696.40Net Income-$21.11M-$52.92M$3.29B$271.62M7 Day Performance-18.07%5.25%3.23%3.33%1 Month Performance40.51%12.05%8.37%10.15%1 Year Performance-38.72%11.76%82.31%31.19% Genprex Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNPXGenprex1.2171 of 5 stars$0.24-2.2%N/A-33.0%$10.21MN/A0.0020Short Interest ↑BCABBioAtla0.5712 of 5 stars$0.69+2.0%N/A-58.4%$39.77M$11M-0.6360EGRXEagle Pharmaceuticals1.4689 of 5 stars$3.06-17.9%N/A-28.5%$39.74M$257.55M0.00100Gap DownATHEAlterity Therapeutics2.0346 of 5 stars$4.38-2.0%$12.00+174.0%+265.0%$39.64MN/A0.0010LVTXLAVA Therapeutics1.4342 of 5 stars$1.47-2.0%$2.69+82.7%-12.5%$39.46M$11.98M-1.4060Negative NewsInsider TradeHigh Trading VolumeXLOXilio Therapeutics1.9939 of 5 stars$0.76+1.3%$3.00+293.0%-6.3%$39.06M$6.34M-1.0070GBIOGeneration Bio3.53 of 5 stars$5.98+3.6%$10.67+78.4%-76.9%$38.86M$19.89M-0.55150Short Interest ↓PYRGFPyroGenesis CanadaN/A$0.20-2.3%N/A-66.9%$38.41M$9.14M-3.3390Gap DownJSPRJasper Therapeutics3.1194 of 5 stars$2.59+11.2%$28.75+1,010.0%-88.6%$37.87MN/A-0.4320News CoverageGap DownHigh Trading VolumePLURPluri2.4912 of 5 stars$4.50-4.3%$12.00+166.7%-13.4%$36.99M$1.34M-0.87150Earnings ReportDYAIDyadic International2.8414 of 5 stars$0.98-1.8%$6.00+511.2%-15.4%$36.19M$3.49M-5.177Positive NewsGap Up Related Companies and Tools Related Companies BCAB Competitors EGRX Competitors ATHE Competitors LVTX Competitors XLO Competitors GBIO Competitors PYRGF Competitors JSPR Competitors PLUR Competitors DYAI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNPX) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genprex Please log in to your account or sign up in order to add this asset to your watchlist. Share Genprex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GNPX Stock Alerts